



ATMA JOURNEY CENTERS

Clinical Trial Team

March 18, 2023

Clinical Trial Information

Bio-disasters, such as SARS, MERS, and now COVID-19, produce an unparalleled strain on frontline healthcare workers. By analyzing the long-lasting impact of prior bio-disasters on mental health, it is evident that a novel approach must be taken to address the resulting mental health concerns of frontline physicians, nurses, psychologists, psychiatrists, etc. from COVID-19. This Phase II Study's primary objective is to demonstrate the efficacy of psilocybin in frontline healthcare professionals who are suffering from COVID-19-related mental health concerns, including major depressive disorder, generalized anxiety disorder, and/or occupational burnout. Standardized questionnaires – QIDS-SR16, the Generalized Anxiety Disorder 7-item (GAD-7), and the Burnout Assessment Tool (BAT) – will be administered to participants prior to and after the psilocybin session to assess improvement in mental state. The secondary exploratory outcome for this study will be the completion of a survey following the experiential session, which will document how effective healthcare professionals believe psilocybin is as a therapeutic tool, based on their firsthand experience.